Q-omics provides the consensus-scored CRABP1 profile across patient tissues and cancer cell-line models. CRABP1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CRABP1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CRABP1 protein abundance shows 14,780 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UCEC, KIRC, and HNSC as cancer lineages where CRABP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRABP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRABP1 survival associations across molecular data types. CRABP1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRABP1 RNA expression–survival associations across cancer types. High CRABP1 expression shows unfavorable associations in UCEC, CESC, LGG and KIRC, but favorable associations in DLBC and THCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CRABP1 RNA expression.
This table summarizes CRABP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CRABP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRABP1 shows lower tumor expression in KIRC, THCA, KIRP, COAD and HNSC and higher tumor expression in UCEC. The KIRC box plot shows higher CRABP1 RNA expression in normal versus tumor tissue (log2 FC = −3.401, t-test p < 0.001).
This table shows molecular features associated with CRABP1 in patient tissues and cancer cell lines. In patient samples, CRABP1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, CRABP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
